INVESTORS

Press Releases

 
Press Releases
  Date Title View
Sep 23, 2016
- ePoster presented today at the EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection — The Roadmap For Cure - - Ongoing Phase 2 development focusing on triple combination for treatment durations as short as six weeks for broad HCV population —...
PDF
Sep 9, 2016
- New data released today in abstract for upcoming EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection — The Roadmap For Cure - - Janssen advancing triple combination into Phase 2b clinical trial - NEW HAVEN, Conn., Sept. 0...
PDF
Sep 6, 2016
NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into complement biology and the inhibition of factor D by ACH-4471 during the XXVIth International Complement ...
PDF
Sep 1, 2016
NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:Baird 2016 Health...
PDF
Aug 11, 2016
NEW HAVEN, Conn., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that interim results from an ongoing phase 2a clinical trial, being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to evaluate all-ora...
PDF
Aug 9, 2016
NEW HAVEN, Conn., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at the 2016 Wedbush PacGrow Healthcare Conference on Tuesday, August 16, 2016 at...
PDF
Aug 4, 2016
NEW HAVEN, Conn. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2016. For the second quarter of 2016, Achillion reported a net loss of $18.5 million or $0.14 per share, compared with a net loss of $...
PDF
Jun 10, 2016
-  Results indicate up to 100% inhibition of alternative-pathway (AP) activity in hemolysis and Wieslab assays after oral dosing of ACH-4471  - -  Results support initiation of phase 1 multiple-ascending trial during the second quarter and phase 2 studies for paroxysmal ...
PDF
Jun 1, 2016
NEW HAVEN, Conn., June 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at three upcoming investor conferences: Jefferies 2016 Healthcare...
PDF
May 19, 2016
- Interim results, including safety, pharmacokinetics and pharmacodynamics, to be presented from ongoing phase 1 single-ascending dose trial with ACH-4471 in healthy volunteers - NEW HAVEN, Conn., May 19, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACH...
PDF
1
...
NextLast